

IN THE CLAIMS:

Please cancel Claims 69-72 without prejudice.

Please amend the remaining claims as follows:

66. (Amended) A diagnostic method for determining the amount of MIF protein in a patient, comprising:

(a) obtaining a bodily fluid sample from the patient; and

(b) determining the amount of MIF in the sample using an immunoassay with an anti-MIF antibody, wherein the immunoassay is selected from the group consisting of ELISA, immunoprecipitation, immunohistochemistry, and Western analysis, and wherein MIF is a human MIF polypeptide having a molecular weight approximately 12.5 kDa, and wherein the anti-MIF antibody binds to the 12.5 kDa human MIF having the amino acid sequence of SEQ ID NO: 5.

67. (Amended) The diagnostic method of Claim 66, wherein the bodily fluid sample is selected from the group consisting of blood, serum, urine, lymph, saliva, tumor tissue, placental tissue, umbilical cord tissue, amniotic fluid, chorionic villi tissue and combinations thereof.

68. (Amended) The diagnostic method of Claim 66, wherein the anti-MIF antibody is a monoclonal antibody or antigen-binding fragment or fusion protein thereof.

REMARKS:

The specification has been amended to reflect the status of the parent applications, as requested by the Examiner.

Applicants acknowledge the finality of the restriction requirement. Non-elected Claims 69-72 are hereby cancelled, leaving Claims 66-68 pending. Applicants expressly reserve the right to pursue the subject matter of Claims 69-72 in an appropriate continuing application.